Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Beneficial effects of pravastatin in peri- and postmenopausal hyperlipidemic women: a 5-year study on serum lipid and sex hormone levels
Autore:
Ushiroyama, T; Ikeda, A; Ueki, M;
Indirizzi:
Osaka Med Coll, Dept Obstet & Gynecol, Osaka 5698686, Japan Osaka Med Coll Osaka Japan 5698686 bstet & Gynecol, Osaka 5698686, Japan
Titolo Testata:
MATURITAS
fascicolo: 3, volume: 37, anno: 2001,
pagine: 201 - 208
SICI:
0378-5122(20010131)37:3<201:BEOPIP>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
LOW-DENSITY LIPOPROTEIN; ISCHEMIC HEART-DISEASE; HMG-COA REDUCTASE; CARDIOVASCULAR-DISEASE; RISK-FACTORS; HYPERCHOLESTEROLEMIA; PERIMENOPAUSAL; CHOLESTEROL; EFFICACY; TRIGLYCERIDES;
Keywords:
pravastatin; hyperlipidemia; endocrine change; menopause; long-term effects;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Ushiroyama, T Osaka Med Coll, Dept Obstet & Gynecol, Osaka 5698686, Japan Osaka Med Coll Osaka Japan 5698686 l, Osaka 5698686, Japan
Citazione:
T. Ushiroyama et al., "Beneficial effects of pravastatin in peri- and postmenopausal hyperlipidemic women: a 5-year study on serum lipid and sex hormone levels", MATURITAS, 37(3), 2001, pp. 201-208

Abstract

Objectives : The aims of the present study are to assess the 5 year effects of pravastatin on serum lipids and lipoproteins in women around the menopause and to assess the effects of pravastatin on serum gonadotropins and sex steroid levels over a long-term period. Methods: We evaluated the long-term efficacy of pravastatin on serum lipid levels (total cholesterol. LDL-cholesterol, HDL-cholesterol, triglyceride) in 121 patients (47 premenopausaland 74 postmenopausal women) suffering from primary hypercholesterolemia. The effects of this lipid-lowering drug on serum gonadotropins and sex steroids (estradiol. estrone, and testosterone) are also reported. Results: Pravastatin produced a remarkable reduction in the serum total cholesterol level of 19.2 +/- 9.3% (P < 0.0001) and 18.9 +/- 11.8% (P<0.0001). and in LDL1-cholesterol of 25.1 +/- 18.71% (P<0.0001) and 24 +/- 18.0% (P < 0.0001) after 24 and 60 months' treatment. respectively. In hypertriglyceridemia. pravastatin also produced a remarkable reduction in triglyceride of 29.3 +/- 27.3% (P<0.0001) and 39.9+/-20.4% (P <0.0001) after 24 and 60 months of treatment. respectively. We found that serum gonadotropins and sex steroid levels changed naturally as a function of age from pre-therapy levels in the premenopausal patients after 60 months of treatment. Conclusions: Pravastatinwas well tolerated over 5 years and was a very effective lipid-lowering agent for both hypercholesterolemia and hypertriglyceridemia with no effect on the biosynthesis of sex steroids. These findings suggest that pravastatincan be used in the treatment of hypercholesterolemia with-without high triglyceride levels in women around the menopause. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 03:19:48